Oncocyte (OCX) filed a registration statement Friday for the resale of up to around 10.6 million shares of its common stock by a selling shareholders from time to time.
About 7.5 million shares for resale were issued in a private placement, while around 3.1 million shares are issuable upon the exercise of pre-funded warrants.
The company said it will not receive any proceeds from the sale of the shares.
It will receive the applicable proceeds from the exercise of the pre-funded warrants, if they are exercised for cash, at an exercise price of $0.001 per share. Oncocyte said it intends to use those proceeds, if any, for general corporate purposes.
Price: 3.04, Change: -0.17, Percent Change: -5.30
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。